The Women's Cancer Program
The Cedars-Sinai Women's Cancer Program, led by Beth Karlan, MD, at the Samuel Oschin Comprehensive Cancer Institute brings together Cedars-Sinai physicians and scientists to focus on how cancer impacts women. This includes both gender-specific cancers (such as breast and ovarian) and other cancers that may affect women differently than men (such as lung cancer).
The Women's Cancer Program offers a wide variety of research studies and clinical trials. The goals of the Women's Cancer Program are:
- To promote research between scientists and physicians to make sure that new laboratory discoveries can help women with cancer as quickly as possible
- To find new drugs and therapies that are personalized to the individual needs of women with cancer
- To identify health behaviors that can reduce the risk of cancer in women
Clinical Therapeutic Trials
The Women's Cancer Program at the Samuel Oschin Comprehensive Cancer Institute currently has many gynecologic clinical therapeutic trials open to accrual. You can search for all trials available at Cedars-Sinai.
The Gilda Radner Hereditary Cancer Program
The Gilda Radner Hereditary Cancer Program, part of the Cedars-Sinai Women's Cancer Program at the Samuel Oschin Comprehensive Cancer Institute, is made up of several research studies for women at highest risk for breast and ovarian cancers — those with the BRCA1 or BRCA2 gene mutations. Founded in 1991, the program brings together a team of physicians who specialize in gynecologic oncology, surgery, radiology, pathology and genetics. Since the program started, over 1,600 women have participated in the program.
Women's Cancer Program Research Laboratories
The Women's Cancer Program laboratories are studying cancer biology with a focus on developing new methods of early detection, prevention and treatments that will improve survival and quality of life for women.
Since 1988, the Women's Cancer Program has maintained a tissue bank to contribute to research efforts at Cedars-Sinai Medical Center as well as research efforts worldwide. The tissue bank currently contains over 100,000 specimens with follow up clinical and survival data that includes over 300 data variables.
The Women's Cancer Program Registry
The purpose of the WCP Registry is to create a large data registry focused on women's cancers:
- To help predict cancer risks.
- To identify participants for clinical trials and studies. Studies may include clinical therapeutic trials for those with a personal history of cancer, screening studies for those without cancer, and other studies that follow individuals over time for data collection.
- To track outcomes of patients who are treated at participating centers and offices to find opportunities to improve care.
Any woman over age 18 can participate in the WCP Registry. The program enrolls women without a history of cancer as well as women with a personal history of cancer. The Women's Cancer Program is working with DocuSign to make it possible for patients to consent and complete the questionnaires online. If you are interested in participating in the registry, please visit Research Cures Cancer.
Maternal Fetal Medicine
The Division of Maternal-Fetal Medicine has research programs in understanding determinants of preterm delivery, early placental tissue, safety in childbirth and maternal severe morbidity. Calvin J. Hobel, MD is analyzing the links between psychosocial and prenatal stresses and preterm delivery. The division has established a biorepository for chorionic villus sampling procedures. Cedars-Sinai is the only institution in the nation that stores placental tissue from the first trimester, so that our researchers can investigate the origins of diseases that affect babies and mothers at the earliest stages of pregnancy.
As the vice chair of Women's Healthcare Quality and Performance Improvement, Kimberly D. Gregory, MD, MPH, has developed maternal quality of care indicators and linked vaginal birth after cesarean delivery policies on labor and delivery to birth outcomes. She continues to evaluate physician behavior and patient views of delivery as it impacts obstetric outcomes. Sarah J. Kilpatrick, MD, PhD, has researched severe maternal morbidity evaluation and potential preventability and continues to work nationally on this area.
The Division of Maternal Fetal Medicine currently has many clinical trials open to accrual. You can search for all trials available.
Reproductive Endocrinology & Infertility
Led by Margareta D. Pisarska, MD, the Division of Reproductive Endocrinology & Infertility is researching the process of ovulation to determine why some women experience early menopause. Specific areas of research involve oocyte development, infertility, and abnormalities in reproductive endocrinology, fibroids and premature ovarian failure.